![Nadim Ahmed](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nadim Ahmed
Amministratore Delegato presso
CULLINAN THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 31/07/2026
Profilo
Mr. Nadim Ahmed is a President, Chief Executive Officer & Director at Cullinan Therapeutics, Inc., a President, Chief Executive Officer & Director at Cullinan Mica Corp.
and a President, Chief Executive Officer & Director at Cullinan Pearl Corp.
He is on the Board of Directors at Disc Medicine, Inc., Cullinan Therapeutics, Inc., Family Promise, Cullinan Mica Corp.
and Cullinan Pearl Corp.
Mr. Ahmed was previously employed as a President, Chief Executive Officer & Director by Cullinan Oncology LLC, a President-Hematology by Bristol Myers Squibb Co., a President-Global Hematology & Oncology by Celgene Corp., and a Senior Marketing Director-Hematologic Oncology by GlaxoSmithKline LLC.
He received his undergraduate degree from the University College London and a graduate degree from Loughborough University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/04/2026 | 135.921 ( 0,23% ) | 2 M $ | 31/07/2026 |
Posizioni attive di Nadim Ahmed
| Società | Posizione | Inizio |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Amministratore Delegato | 18/10/2021 |
| DISC MEDICINE, INC. | Direttore/Membro del Consiglio | 14/07/2025 |
Family Promise
 Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Direttore/Membro del Consiglio | - |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Amministratore Delegato | - |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Amministratore Delegato | - |
Precedenti posizioni note di Nadim Ahmed
| Società | Posizione | Fine |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2021 |
| CELGENE | Corporate Officer/Principal | 01/11/2019 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01/03/2010 |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Amministratore Delegato | - |
Formazione di Nadim Ahmed
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
80
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loughborough University
 Loughborough University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Commercial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Health Technology |
Cullinan Oncology, Inc.
 Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
 Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
